More short articles on pharmacy: CVS partnering with Delta Air Lines for fast COVID-19 screening programSanofi inks $3.68 B offer to purchase California autoimmune drugmakerUS to test advantages of remdesivir with 2nd drug.
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by clicking here.
Maia Anderson –
Tuesday, August 18th, 2020
The stage 1 trial was investigating a CAR-T gene therapy called P-PSMA-101, developed to treat prostate cancer..
The FDA stopped San Diego-based drugmaker Poseida Therapeutics scientific trial of a CAR-T treatment after a client died, according to an Aug. 17 Securities and Exchange Commission filing.
Poseida is waiting on a formal reaction from the FDA and preparing recommendations to permit the trial to resume, the drugmaker said..
The drugmakers shares fell 35 percent after the announcement.
The patient had metastatic castrate-resistant prostate cancer and died of liver failure 19 days after getting the CAR-T treatment. He had actually missed 2 follow-up gos to and established symptoms that caused him being hospitalized, according to the SEC filing..